A Detailed Analysis of the Dysmenorrhea Treatment Market Based on Increasing Awareness, and Advancements in Therapeutic Options
Report ID: PMRREP34024
Number of Pages: 246
Format: PPT*, PDF, EXCEL
Industry: Healthcare
Published Date: February-2024
The global dysmenorrhea treatment market is forecast to expand at a CAGR of 8.5% and thereby increase from a value of US$5.6 Bn in 2023, to US$10 Bn by the end of 2030.
|
Attributes |
Key Insights |
|
Dysmenorrhea Treatment Market Size (2023E) |
US$5.6 Bn |
|
Projected Market Value (2030F) |
US$10.0 Bn |
|
Global Market Growth Rate (CAGR 2023 to 2030) |
8.5% |
|
Historical Market Growth Rate (CAGR 2018 to 2022) |
5.5% |
Report Sample is Available
In-depth report coverage is now just a few seconds away
Get Report Sample
Dysmenorrhea, a medical term for severe menstrual cramps, is characterized by intense abdominal pain that may radiate to the lower back and legs. Typically, onset during adolescence, after several years from the first menstrual cycle, dysmenorrhea is attributed to the production of prostaglandins in the uterine lining during menstruation. These prostaglandins induce uterine muscle spasms, resulting in discomfort, reduced blood supply, and decreased oxygen to the uterus. Various underlying conditions can contribute to menstrual issues.
The increased prevalence of dysmenorrhea is influenced by lifestyle modifications, environmental changes, and dietary preferences, impacting women's overall health. This rise in dysmenorrhea cases has prompted heightened health awareness among women seeking effective treatments, thereby fostering growth in the market.
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized VersionExpanding Burden of Dysmenorrhea
Market growth is primarily driven by the escalating prevalence of dysmenorrhea among adolescent girls and a surge in cases of menstrual cramps attributed to genetic disorders. A study published in March 2022 in BMC Women's Health revealed that among the observed cases, 92.3% of women experienced non-pathological dysmenorrhea (primary), while 7.7% had pathological dysmenorrhea (secondary).
Another study in February 2021 by BMJ Open highlighted dysmenorrhea as a common health issue among graduating university students, with a prevalence of 51.5% in Ethiopia. Factors like the father's educational status, chocolate consumption, irregular menstrual cycles, and positive family history of dysmenorrhea showed statistically significant associations. The expanding burden of dysmenorrhea is poised to drive market growth throughout the forecast period.
High Costs of Care
The absence of healthcare facilities in developing countries and strict regulations may pose difficulties for the worldwide industry. Additionally, throughout the projected period, weak reimbursement rules and a lack of public awareness may impede market progress. The high morbidity of menstrual cramps due to inadequate treatments, obstacles connected to long-term care and other side effects and difficulties, and traditional family values are anticipated to impede the expansion of the global market.
Persistent Stigma and Cultural Taboos
A significant challenge in addressing dysmenorrhea is the enduring presence of stigma and cultural taboos surrounding menstruation. In numerous societies, menstruation remains a taboo subject, creating challenges for women to openly discuss their symptoms and seek appropriate treatment. This cultural barrier can dissuade women from seeking medical assistance, contributing to delayed diagnosis and treatment.
Dysmenorrhea is occasionally misidentified as a normal aspect of the menstrual cycle, leading to underdiagnosis. Many women may not perceive their symptoms as abnormal or may lack access to healthcare professionals capable of providing an accurate diagnosis. This can result in inadequate treatment and prolonged suffering for those affected.
The Rise of Nonsteroidal Anti-inflammatory Drugs
The expanding global female population and the heightened awareness of menstrual health among girls in emerging economies are generating opportunities for the dysmenorrhea treatment industry. The demand for nonsteroidal anti-inflammatory medications (NSAIDs) is on the rise with the increasing incidence of primary dysmenorrhea. NSAIDs inhibit the formation of cyclooxygenase-mediated prostaglandin, a major contributor to menstrual discomfort.
Additionally, NSAIDs help reduce menstrual flow volume, thereby alleviating back and abdominal pain in patients. Healthcare professionals commonly recommend NSAIDs such as ibuprofen, naproxen sodium, mefenamic acid, and celecoxib. Furthermore, industry participants are enhancing NSAIDs to deliver precise and effective medications with minimal adverse effects.
The market is anticipated to undergo substantial expansion and change. Several government entities aim to enhance healthcare infrastructure through increased funding, influencing market revenue growth. The rising volume of research and development (R&D) activities is a key driver of market revenue growth, presenting favorable opportunities for expansion in the menstrual cramps therapy sector. Major corporations are strategically investing in R&D, creating significant market prospects that are anticipated to propel revenue growth throughout the forecast period.
Supply-side Dynamics
Several factors, including the increased consumer awareness of dysmenorrhea therapy, as well as the low cost of over-the-counter medications, all contribute to the dynamic and rapid expansion of the global Dysmenorrhea Treatment market. Novartis Pharmaceuticals Corporation, Merck, Inc., Bayer Schering Pharma AG, Vanita Therapeutics, and Alvogen are market leaders in the manufacturing sector.
The countries of Germany, Japan, China, France, and the US are significant producers of various goods. In the US, the expansion of research and development initiatives to create new pharmaceuticals and evaluate the efficacy of existing therapies is expected to enhance the relevant market. In Germany, the growth of healthcare infrastructure and increasing government initiatives may expedite the market's growth trajectory in this region.
Several companies have been involved in developing and launching new drugs while also creating awareness about the prevalence of dysmenorrhea and its treatment. It is anticipated that these expansions will substantially alter the dynamics of the market, resulting in heightened competition, reduced prices, and an influx of innovative products. It is anticipated that expanding capacity will exert a substantial influence on market dynamics, resulting in heightened competition, reduced prices, and an increased availability of innovative products.
Which is the Leading Market Segment Based on Disease?
Primary Dysmenorrhea Leads as the Most Widely Prevalent Disease
Primary dysmenorrhea is positioned to be the leading segment in the global dysmenorrhea treatment market in 2022 due to several compelling factors. It represents the most prevalent form of dysmenorrhea, impacting a significant portion of the global female population. This widespread prevalence ensures a consistently high demand for treatment options, thereby driving market growth. Primary dysmenorrhea is often a chronic condition, requiring continuous management and treatment, further solidifying its dominance in the market.
Additionally, as healthcare awareness and accessibility continue to improve globally, an increasing number of individuals seek medical intervention for menstrual pain, contributing to an expanded patient pool and market expansion. Lastly, ongoing research and development efforts aimed at introducing innovative and more effective treatment modalities for primary dysmenorrhea will reinforce its market leadership by providing patients with improved options for pain relief and management.
Which is the Dominant Therapeutic Class?
NSAIDs Bestseller for Effective Pain Management During Cramps
Using over-the-counter pain relievers like ibuprofen (Advil, Motrin IB, others) or naproxen sodium (Aleve) at regular doses, starting the day before the anticipated onset of the menstrual period, can effectively manage the pain associated with cramps. Several NSAIDs approved by the US FDA for treating dysmenorrhea include diclofenac, ibuprofen, ketoprofen, meclofenamate, mefenamic acid, and naproxen.
As highlighted in an article published by Women's Health Concern and the British Menopause Society in December 2020, about 80% of women experiencing dysmenorrhea encounter period pain at some point in their lives. Premenstrual symptoms accompany period pain in 40% of women, leading to symptoms like bloating, tender breasts, swollen stomach, lack of concentration, mood swings, clumsiness, and fatigue. Hence, early treatment of dysmenorrhea is crucial, expectedly boosting the utilization of NSAIDs and driving growth in this segment.
Rapidly Escalating Dysmenorrhea Incidence Earns Top Spot for the US, Thereby North America
The US is poised to make a substantial contribution to the growth of the dysmenorrhea treatment market, driven by an escalating incidence and prevalence of dysmenorrhea along with increased awareness among women. According to November 2020 statistics from Simmons Winter NHCS 12-Month, 31.31 million women in the US reported experiencing menstrual/period pain or pre-menstrual syndrome (PMS) in 2020. Additionally, the introduction of novel products for managing pain associated with both primary and secondary dysmenorrhea is a key factor propelling market expansion.
For instance, in May 2021, the US FDA approved Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg), marking the first once-daily treatment designed for the management of heavy menstrual bleeding linked to uterine fibroids in premenopausal women, with a treatment duration of up to 24 months.
What Opportunities Lie in Europe for Manufacturers?
Europe on a Rapid Progression Trail, Various EU Initiatives Drive Growth
In the European market, clinical trials aimed at addressing the discomfort associated with dysmenorrhea are anticipated to yield more effective treatments for the condition throughout the forecast period. Furthermore, the exclusivity granted by regulatory bodies to manufacturers of innovative and safe products contributes towards prolonged revenue generation. In 1990, Bayer AG (Germany) introduced Mirena, the inaugural intrauterine contraceptive releasing levonorgestrel, initially in Finland.
Moreover, in August 2020, the US FDA approved Mirena to be used for six years to alleviate menstrual cramps. The various initiatives undertaken by the European Union to offer essential medication, shelter, and rehabilitation to residents fleeing politically unstable nations present opportunities for manufacturers to negotiate extended-term supply contracts.
Prominent organizations, including Novartis Pharmaceuticals Corporation, Merck, Inc., and Bayer Schering Pharma AG are at the vanguard of this sector, providing inventive solutions by capitalizing on investing in research and development. Organizations operating within this sector prioritize technological advancements, strategic alliances, and user experience improvement.
The dynamic growth of the dysmenorrhea treatment market is attributed to technological innovations in pain management and ongoing research and development activities. This reflects a commitment to addressing menstrual health concerns with improved and personalized solutions. To distinguish themselves in this highly competitive market, these businesses strive to differentiate their products. They achieve this by providing distinctive attributes, enhanced precision, and more extensive health observations.
New Product Launch
In August 2021, Dr. Reddy's Laboratories Ltd reintroduced the over-the-counter (OTC) Naproxen Sodium Tablets USP, 220 mg, in the United States for addressing minor pain, including menstrual cramps.
Market Impact: Dr. Reddy's Laboratories Ltd.'s reintroduction of the over-the-counter Naproxen Sodium Tablets in August 2021 is anticipated to propel the dysmenorrhea treatment market by offering a convenient and efficacious remedy for mild discomfort, namely cramping during menstruation. This reintroduction expands the range of therapeutic options available to those who have dysmenorrhea, which in turn promotes market growth by meeting the growing demand for over-the-counter drugs that address menstruation discomfort.
In December 2020, Nua introduced Cramp Comfort, an innovative period pain relief solution, marking a significant advancement in addressing menstrual discomfort. The women's health startup unveiled a pioneering self-heating patch designed to provide up to 8 hours of heat for relieving period pain. Composed entirely of natural ingredients, Cramp Comfort reflects extensive research and a thorough understanding of customer needs. The product, priced at INR 299 for a pack of three heat patches, offers a unique and effective approach to alleviating menstrual discomfort.
Market Impact: Nua addresses a significant component of menstruation health by providing a unique and efficient self-heating patch made especially for the treatment of period discomfort. The special features-like the longer heat delivery duration and the use of natural ingredients-adjust to the changing needs and tastes of customers. As these products become more widely used, they support the expansion of the dysmenorrhea treatment market by giving people customized, cutting-edge options for treating menstrual discomfort.
|
Attribute |
Details |
|
Forecast Period |
2023 to 2030 |
|
Historical Data Available for |
2018 to 2022 |
|
Market Analysis |
US$ Million for Value |
|
Key Regions Covered |
|
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon request |
By Diseases:
By Therapeutic Class:
By Region:
For report customisation and delivery information contact our sales representative.
